Claims for Patent: 9,358,303

Summary for Patent: 9,358,303

Title:	Compounds containing a vascular disrupting agent
Abstract:	The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Inventor(s):	Gill; Jason (Bradford, GB), Loadman; Paul (Bradford, GB), Falconer; Rob (Bradford, GB), Patterson; Laurence (Bradford, GB), Xavier; Jennifer (Needingworth, GB), Bibby; Michael (Bradford, GB)
Assignee:	Incanthera Ltd (Bradford, GB)
Application Number:	14/109,333
Patent Claims:	1. A method of treating cancer in a subject comprising administering to the subject an effective amount of a compound comprising a vascular disrupting agent (VDA), linked to a peptide comprising a matrix metalloproteinase-14 (MMP-14) proteolytic cleavage site comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- (SEQ ID NO: 4) or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 wherein the cancer is a solid tumor. 3. The method of claim 2 wherein the cancer is a carcinoma or a sarcoma. 4. The method of claim 2, wherein the cancer is selected from the group consisting of cancer of the mouth, nose, trachea, lung, tongue, esophagus, stomach, small intestines, colon, liver, pancreas, gall bladder, rectum, thyroid, pituitary, adrenal glands, urinary bladder, kidney, breast, ovaries, uterus, cervix, prostate, penis, scrotum, testes, skin, brain, spinal cord, glial cells, neurons and lymphoid system. 5. The method according to claim 1 wherein the compound is of formula (I) X--Y (I) wherein X is the VDA and Y is the peptide comprising a MMP proteolytic cleavage site. 6. The method according to claim 1 wherein the VDA is an anti-cancer agent. 7. The method according to claim 1, wherein the VDA has cytostatic or cytotoxic effect. 8. The method according to claim 1, wherein the VDA is selected from colchicine, a colchicine analog, colchicinoid, combretastatin, phenstatin, podophyllotoxin, steganacin, amphethinile, stilbene and flavonoid. 9. The method according to claim 1, wherein the VDA is selected from the group consisting of colchicine, azademethylcolchicine, azacolchicine, N-methyl desacetylcolchicine and desacetylcolchicine. 10. The method according to claim 1, wherein the VDA is a vincristine, vinblastine, vinflunine, maytansinoid, phomopson A, rhizoxin, auristatin, auristatin analog or dolastatin. 11. The method according to claim 1, further comprising administering to the subject an effective amount of another therapeutic agent. 12. The method of claim 11, wherein the another therapeutic agent is selected from the group consisting of cisplatin; carboplatin; cyclosphosphamide; melphalan; carmustine; methotrexate; 5-fluorouracil; cytarabine; mercaptopurine; daunorubicin; doxorubicin; epirubicin; vinblastine; vincristine; dactinomycin; mitomycin C; taxol; L-asparaginase; G-CSF; etoposide; colchicine; derferoxamine mesylate; and camptothecin. 13. A method of treating cancer in a subject comprising administering to the subject an effective amount of a compound comprising a vascular disrupting agent (VDA) selected from the group consisting of colchicine, azademethylcolchicine, azacolchicine, N-methyl desacetylcolchicine and desacetylcolchicine, wherein the VDA is linked to a peptide comprising a matrix metalloproteinase-14 (MMP-14) proteolytic cleavage site comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- (SEQ ID NO:4) or a pharmaceutically acceptable salt thereof. 14. The method of claim 1, wherein the cancer is colorectal, lung, breast, or prostate cancer. 15. The method of claim 1, wherein the VDA is azademethylcolchicine. 16. The method according to claim 1, wherein the peptide comprises a capping group on the N- or C-terminus. 17. The method of claim 16, wherein the capping group is a simple sugar, a D-amino acid, a proline imino acid, fluorescein, or a fluorescein derivative.

Details for Patent 9,358,303

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-04-12